Amsterdam, The Netherlands, June 12, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, announced that new data related to its K-NK cell therapy platform will be presented today at the virtual edition of the 25th European Hematology Association (EHA) Congress. Abstract #S284 is an oral presentation that shows clinical data from several phase I/II studies demonstrating that ex vivo expanded K-NK cells persist and proliferate in vivo for up to five weeks. The poster for abstract EP1487 presents data that demonstrate K-NK cells expanded with FC21 or PM21 are distinct from non-expanded NK cells in phenotype and gene expression signature and are highly cytotoxic, with elevated levels of cytokines. Finally, a poster (abstract #EP585) describes positive clinical outcomes in a subset of R/R AML patients treated with K-NK cells expanded with FC21 following chemotherapy that were enrolled in a phase I/II study with concomitant infections.
- An oral presentation (abstract #S284) shows clinical data that K-NK cells persist and proliferate in vivo
- A poster presentation (abstract #EP1487) presents data that demonstrate uniformity of K-NK cells expanded with FC21 (as used in past clinical trials) or PM21 (industrial platform to be used in future clinical trials including NK-REALM), which are distinct from non-expanded NK cells in phenotype and are highly cytotoxic, with elevated secretion of cytokines
- An additional poster presentation (abstract #EP585) describes data from a phase I study of infusions of K-NK cells expanded ex vivo with FC21 following chemotherapy that show evidence of anti-microbial activity in patients with relapsed or refractory acute myeloid leukemia (R/R AML)